Compare FMS & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMS | MEDP |
|---|---|---|
| Founded | 1996 | 1992 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 13.4B |
| IPO Year | 1996 | 2016 |
| Metric | FMS | MEDP |
|---|---|---|
| Price | $23.60 | $559.61 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 12 |
| Target Price | $30.00 | ★ $468.82 |
| AVG Volume (30 Days) | ★ 475.7K | 274.1K |
| Earning Date | 11-04-2025 | 10-22-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | 8.62 | ★ 25.36 |
| EPS | 2.86 | ★ 14.32 |
| Revenue | ★ $23,046,819,198.00 | $2,358,373,000.00 |
| Revenue This Year | $2.12 | $21.48 |
| Revenue Next Year | $2.92 | $11.90 |
| P/E Ratio | ★ $16.00 | $39.02 |
| Revenue Growth | 2.10 | ★ 13.88 |
| 52 Week Low | $22.05 | $250.05 |
| 52 Week High | $30.46 | $626.26 |
| Indicator | FMS | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 43.78 |
| Support Level | $22.63 | $544.24 |
| Resistance Level | $23.88 | $569.00 |
| Average True Range (ATR) | 0.29 | 15.33 |
| MACD | 0.14 | -2.56 |
| Stochastic Oscillator | 72.79 | 36.66 |
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.